Get started

Biotech

FLMD biotechology rising post earningsFLMD had earnings in May with positive earnings beating the expectation of analysts that it would continue to lose quarter after quarter. Investors and traders have reacted with a 80% run-up in the month after those earnings. On the 30-minute chart besides the consistent uptrend with minor corrections, what stands out for me is the increasing volumes relative to volumes before the last earnings report. Off the chart, I find information that insider trading with buying more shares on top of existing holdings leads me to believe that this company expects increasing revenues and sustained earnings.
NASDAQ:LFMDLong
by AwesomeAvani
AUTL Is this a pump and dump?AUTL on the one-hour chart had a spontaneous parabolic move without a catalyst as best as I can tell. Earnings ten days ago were decent but nothing special. AUTL as a biotech firm is losing cash just not as much as analysts predicted. In the parabolic move very few shares were traded between $2.00 and $2.40 as per the volume profile Overall a massive volume occurred compared with the entire year although there was a bit in the runup to earnings. I suspect a pump and dump and think it might be worth playing. Insiders could be manipulating the shares and acting as a team. The zero-lag MACD suggests that the top has been reached. I believe that insiders will be selling quickly and short sellers will be joining in. I will be one of the latter. Retail buyers could be stuck bag holding if caught by surprise. Once price drops to $4.00 the bearish momentum will kick in due to the volume void on the profile. Accordingly, I will buy a group of call options when AUTL hits $4.05 set a stop loss and await the flush back down to $2.00. If things go well this will be over a 100% return on investment and 300% return on risk in one day. The contracts for 6/16 ( $5.00) are about $250 with about 25% spread between the bid and ask.
NASDAQ:AUTLShort
by AwesomeAvani
Pullback Buy in TGTXBiotech stocks can make huge moves, and this one is no exception. TGTX more than doubled in a month and is showing no signs of slowing down. Slower-trending, blue chip stocks tend to ride their 50-day moving average (red line on chart) on the way up. Stronger stocks tend to hold their 21-day moving average (blue line). But with high-flying honey badger stocks like TGTX, you are lucky to get a pullback to the 10-day (yellow line). TGTX touched its 10-day exponential moving average on Friday, making this the first real pullback buying opportunity since the initial surge. I would consider buying here with an 8-10% stop loss.
NASDAQ:TGTXLong
by rossgivens
VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked) approximately a doubling of the shart price in the next year. Like many low share priced biotechnology stocks the price is based on perceived future earnings which can be affected by favorable FDA process, or well-received research at industry conferences and changing financials within the company. In general, they have a low beta meaning these stocks are not general market responsive and run on their own present or future merits. On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green. I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology trades long with a high R:R due to the inheret risk level.
NASDAQ:VYNE
by AwesomeAvani
BLUE Biotechnology New Earnings Catalyst LONGBlueBird Bio / BLUE had an earnigns report this past week showing earnings for the firat time but revenue was far below analyst's projections. Price has appreciated 40% in the 4 weeks since earnings which is about 500% annualized. GO BLUE. On the daily chart, price was above VWAP and consolidating much of last fall then dropped this YTD until the earnings report of last week. An uptrend is seen after the earnings. This has been a significant reversal sustained over the past month with price rising above the support / demand zone below it. At present, price is one standard deviation below VWAP making it undervalued and ascending. I see this as a risky long trade like many biotechology penny stocks but with a decent probability of profit in consideration of a target of 6.15 which is the top of the long term high volume area. the stop loss is just below the POC line of the volume profile at 3.15 An entry at 4.62 ( limit order above SMA200 (redlne) would yield at profit of 1.50 with a risk of 0.48 making for a R:R of 3:1. Another earnings report is coming up this week. If it is favorable, BLUE could go parabolic to hit the target in a day or two. If not, it will be time to exit the trade.
NASDAQ:BLUELong
by AwesomeAvani
7
Cathie Wood is long BEAM, But I will be Strong Short #CathieWood Baught this stock...I analyzed it....and …...well....I would do exact the opposite...... But why? Technical Analysis Let forget eveything you know about technical analysis, and let together tell this story....logically.. At 76-71 USD AGGRESSIVE SELLERS FORCED THE PICE DOWN 29,72 USD BUYERS DEFENDED THIS Area(ZONE) as well the sellers took partial profits, and accumulated their positions ,but this time more powerfully and aggressive at 64-61USD zone THE PRICE MOVED DOWN, Institutional buyers took patial profits,(the best decision they could do OTHERWISE THEY WOULD LOSE ALL THIER PROFITS LOOK AT THE PICE OF TODAY The retail traders who followed the news and the hype baught Beam hoping that the share prce will fly to the moon,but...... At 64-61 who is waiting there? YES THE AGGRESSIVE SELLERS!!!! NOW THEY FORCED MUCH MORE ORDERS TO SEND THE PRICE To the....where we are now.... Bad for the buyers...Some buyers took profits, some took losses, and to compensate thier losses, they started to sell short the market.... At 28,80(YELLOW LINE) we are now at the weak support(low volume) The market could make a retracement to 44,94USD where the sellers and BEARS are waiting of them.....to do what? Well you know it..... Otherwise...more selles (former retail trades bulls) could decide to sell the maket from here.... WE HAVE A LONG DISTANCE TO GO DEEPER.... Targets short 13,75 8,68 3,82 1,25 . . Wood's flagship ARK Innovation ETF has loaded up in recent weeks on Beam Therapeutics (BEAM 1.11%). The gene-editing stock currently ranks as the ETF's 18th-largest holding. It's also the ninth-largest position in Wood's ARK Genomic Revolution ETF. Beam Therapeutics is a pioneer in base editing. Most types of gene editing involve double-strand breaks in DNA that can cause random unwanted insertions and deletions. Base editing is highly precise, with no double-strand breaks and no off-target genetic changes. Because of these characteristics, base editing holds tremendous promise as a method for developing therapies targeting genetic diseases and "off the shelf" cell therapies for treating cancer. So far, Beam has advanced two base-editing candidates into clinical testing. It's evaluating BEAM-101 as a treatment for two rare blood disorders: sickle cell disease and beta-thalassemia. And the company expects to begin dosing patients in a phase 1 study of experimental cancer cell therapy BEAM-201 by mid-2023. Those two programs could be joined by two others soon. Beam hopes to submit for regulatory approvals to start clinical studies of BEAM-301 as a treatment for glycogen storage disease type 1a and BEAM-302 as a treatment for severe alpha-1 antitrypsin deficiency by early 2024. The company has a long way to go. But if its base-editing programs prove to be safe and effective, Beam could be a massive winner.
CAPITALCOM:BEAMShort
by DaveBrascoFX
1
MRNA ? Buy Weakness MRNA descended this past winter off a head-and-shoulders pattern on the daily chart just under the demand zone as shown by the LuxAlgo indicator. Price is now in a downtrend heading into earnings tomorrow. MRNA needs to show something good otherwise it will break through the demand zone and keep going down. This is a risky earnings play betting that something will show up on the report to buoy up the company and its stock. I will risk 0.01% of the trading account on a call option with DTE 5/19/23 looking for a minor surge and so a good quick profit. ( see also the link below)
NASDAQ:MRNALong
by AwesomeAvani
LABU Triple Leveraged Biotech Sector ETFOn the 4H Chart LABU is trending up since March 27th. Last week there was a small pullback which was met with more buying activity. On the volume indicator, the volume now is approximately 10X day by day compared with March's averages. It is this buying that is driving the bullish momentum. Small-cap speculative biotech companies are in a growth mode right now no matter adverse economic conditions for those yet to have any earnings. Big pharma is more concerned about federal attempts to further regulate prices than the economy. On the volume profile, price has ascended to above the high volume trading area on the strength of buyer interest propelling the momentum. Overall, this looks to be a decent long trade. The target is $ 9.00 the YTD high back in February.
AMEX:LABULong
by AwesomeAvani
GOSS Penny Biotechology SHORTGOSS is a biotechnology penny stock without earnings valued based on future earnings potential based on a "pipeline" which is subject to a long timeline of FDA regulation. On the 30 minute chart. price is shown as being in the overvalued area in the upper VWAP band and well above the POC line of the long-range volume profile. The RSI indicator is now showing a bearish divergence as the relative strength is weakening. Price has bounced down from the resistance of the line representing two standard deviations above VWAP. The supply / demand zones are indicated by the Indicator applied which is authored by Luxalgo. Price has hit the supply zone lower border and is now in an early reversal. I see this as a swing short trade also played with taking put options. Stop loss is in the upper area of the red supply zone. Targets include first the POC line of the volume profile and then a final target at one STD below VWAP also being just above the demand zone. Alternatively put options at the strike of $ 1.50 for the May monthly expiration of 5/18 This trade will benefit from any expected pullback in the general markets.
NASDAQ:GOSSShort
by AwesomeAvani
LABD 3X BEAR BIOTECH LONG DAYTRADEAs shown on the 15-minute chart, LABD is bouncing between stardard deviations of the VWAP in a 6% price range fluctuation day to day. At the upper end it is reversing at the POC of the volume profile confluent with one standard deviation above VWAP while at the bottom it is bouncing from the bottom of the lower high volume area of the profile and two standard deviations below VWAP. I see this as an opportunity for a 6% upside long day trade especially if the general market is uptrending after the weekend. Alternatively, a 5 DTE call option with a strike of $ 15.50 or $16.00 looking for a 30-40% return on the premium over the upcoming week. ( The zero lag MACD confirms the buy signal.)
AMEX:LABDLong
by AwesomeAvani
ACHV a Biotech company after earningsACHV on the 4H seems to be demonstrating a "High Bull Flag Pattern" after a big uptrend to start the year. Earnings on Thursday 3/16 were quite favorable.On the relative volume indicator Friday, May 17th showed a paradoxical huge selling volume spike to finish out this week. ( I mislabelled this as upcoming on the chart) Paradoxically, the last earnings report in November was poor but resulted in strong upward price action. The MACD histogram is at the zero line. Will ACHV resume the uptrend after earnings? Was the selling volume an institutional trader fake out to set up a lower price to buy call options? According to Tip Ranks, the analysts give ACHV a high rating with significant upside. See the link below Who knows but this may be worth watching for signs of buying volume and accumulation to fuel bullish momentum.
NASDAQ:ACHV
by AwesomeAvani
1
SIGA a Biotech breakout last summer- then breakdown ? reversalAs shown on the daily chart dating back to last summer SIGA has been on a persistent decline since the cooling down from the parabolic breakout last summer. Is there a repeat in the picture? Fundamentally, earnings continue to be weak. much of the stock is held by insiders and the whole monkey pox thing is settled down although the main product may have use in malaria, leper's disease or whatever other orphan use it has indications by the FDA and its foreign counterparts. The technical picture is that it is sitting just above support shown by the Supply Demand Zone indicator of Luxalgo having double bottomed and now a bit above it. The volume indicator shows a mild increase in buying volume in the past couple of weeks. Price is more than one standard deviation below the long-term anchored VWAP in the undervalued over-sold zone. With a weak biotechnology company where insiders have a fair portion of the shares, manipulation can occur. Once a price rise issues short sellers will buy to cover, and retail traders will jump on board, insiders will "manufacture" a catalyst to prime the pump further. At some point, the run-up will stall, and the implode itself. I will get on the ride early, a biotechnology speculative trades are in my playbook. The stop loss here is below the demand zone while the target is the 50% retracement of the downtrend drawn onto the chart by the Fibonacci Retracement tool.
NASDAQ:SIGALong
by AwesomeAvani
EYPT EyePoint Pharmaceutics LONGEYPT is now on another breakout on the 2h chart similar to what occurred from mid-December to mid-January. On the indicators the MACD shows the K/D lines on a steep upward slope. For me, what set off my interest was a relative volume scan that produced this stock on the list. The relative volume this week and consequential accumulation triggered the breakout with those volume spikes Fundamentally, EYPT had a catalyst as it completed one phase of its FDA clinical trials for a treatment for macular degeneration, a debilitating eye disease of the elderly. The potential market is several multiples of the stock's current market cap. This company is a takeover candidate as it is young without a big pipeline but with upside potential. The relative volume of 4X to 8X is a sure sign that buying pressure will move the price. Price has crossed the SMA50 just as it did last winter. The price is up 40% or more this week. Could this be a pump and dump? Maybe. For sure it is a speculation play just like many NASDAQ penny biotech stocks For mem the price action of last winter with a 120% gain in one month is reassurance for this time around with some hopeium thrown into the mix with the technical analysis. I will buy a call option under the current price with the 4/21 expiration and leverage the speculation a bit. In the past day, this option rose 67% based on the price surge of the underlying stock.
NASDAQ:EYPTLong
by AwesomeAvani
3
Harvard Bioscience: Bouncing Higher From Multiple-Year SupportI zoomed all the way out to the monthly chart to show the long-term support levels. We can see that HBIO is bouncing higher from a multi-year support level in the $2 range. The MACD (middle of the chart) didn't confirm an upward trend yet. However, the MACD did confirm the upward trend on the weekly chart. It looks like the blue monthly MACD line is close to crossing above the red signal line. The purple RSI line on the bottom of the chart is pointing upward, which is bullish. This indicates that we could see a long-term continuation of the rally which began in December/January. Click on the link below for a detailed article. HBIO has a low valuation with strong expected EPS growth. This is likely to drive the stock higher IMO.
NASDAQ:HBIOLong
by Zman1175